Table 4.
Utilities and disability weights
| Economic evaluation | Source | Population surveyed | Country | Methods | Sample size | Results |
|---|---|---|---|---|---|---|
| Brown (1992) [22] | Assumed | None | NR | Assumed | NA | Hearing problems* TP: 0.6 TP10: 0.5 HL: 0.3 HL10: 0.2 FN8: 0.1 FN10: 0.0 No hearing problems** TN8: 1.0 TN10: 0.95 NSW10: 0.925 NSW: 0.9 SW10: 0.875 SW: 0.85 FP8: 0.8 |
| Herrero & Monero-Ternero (2002)a [30] | Assumed | None | Spanish tariffs used | Assumed | NA | EQ-5D*** [for 0.11% prevalence] TNHS1: 0.0019 TNHS2: 0.0022 TNHS3: 0.0021 UNHS1: 0.0033 UNHS2: 0.0038 UNHS3: 0.0035 HUI3*** [for 0.11% prevalence] TNHS1: 0.0032 TNHS2: 0.0037 TNHS3: 0.0034 UNHS1: 0.0054 UNHS2: 0.0062 UNHS3: 0.0058 |
| Grill et al. (2006) [33] | Expert opinion | None | UK | Expert opinion | NR | Detected < 6 months: 1.0 Not detected in one year: Moderate: 0.90, Moderate/month: 0.875 (50% of hearing disorder considered moderately impaired) Severe/profound: 0.85 |
| Huang et al. (2012) [43] | Mathers et al. [54] | None | NR | Expert opinion | NR | Treated: 0.216 Untreated: 0.168 |
| Tobe et al. (2013) [44] | Mathers et al. [54] | None | NR | Expert opinion | NR | NR |
| Fortnum et al. (2016) [45] | Barton et al. [59] (for severity) | Hearing impaired adults (before and after hearing-aid provision) | UK | EQ-5D Health Utilities Index Mark III SF-6D |
609 patients | Moderate 0.677 Severe: 0.616 Profound: 0.485 |
| Fortnum et al (2016) [45] | Bisonni et al. [60] (for grommet surgery) | None | None | None | None | Grommet surgery 0.995 |
| Fortnum et al. (2016) [45] | Assumed (for mild, minimal, conductive hearing loss and hearing aid) | Assumed | UK | Assumed | NA | Minimal: 1.0 Mild: 1.0 Conductive (unilateral/bilateral): 0.677 Hearing aid: 1.0 |
| Fortnum et al. (2016) [45] | Summerfield et al.[61] for unilateral and bilateral | Adult patients undergoing unilateral implantation and general population |
UK | Patients: Mark III (HUI3) General population: TTO |
Patients: 202 General population: 70 |
Cochlear implant: Bilateral: 0.965 Unilateral: 0.934 |
| Chiou et al. (2017) [46] | Wake et al. [58] | Children with fitted hearing aid for congenital HL, 7–8 years (n = 89) | Australia | CELF language scores | 89 | Mild: 0.888 Moderate: 0.827 Severe: 0.744 Very severe: 0.597 |
| Rivera et al. (2017) [49] | Mathers et al. [54] | None | NR | Expert opinion | NR | Treated: 0.12 Untreated: 0.333 |
CELF Clinical Evaluation of Language Fundamentals, DALY disability-adjusted life year, HL hearing loss, HUI3 Health Utilities Index Mark 3, NA not applicable, NR not reported, NSW well but no symptoms, QALY quality-adjusted life year, QCM quality-adjusted child months, SF-6D Short-Form Six-Dimension, SW well but having symptoms, TNHS Targeted Newborn Hearing Screening, UK United Kingdom, UNHS Universal Newborn Hearing Screening
TP: True positive; FN: False negative; HL: children with hearing loss; 8 and 10 represent screening at 8–9 months and at 10 months, respectively
TN: True negative; FP: False positive; 8 and 10 represent screening at 8–9 months and at 10 months, respectively
Utilities for 0.35% not presented here
TNHS1 and UNHS1 protocol involved screening by TEOAE followed by AABR; UNHS2 and TNHS2 involved screening by OAE followed by S-ABR; TNHS3 and UNHS3 involved screening by 3-stage OAE